Atomic AI is an emerging biotechnology company exploiting the fusion of artificial intelligence and structural biology to unlock RNA drug discovery. Based on research prominently featured in Science, Atomic AI’s R&D platform leverages state-of-the art deep learning algorithms, integrated in a virtuous cycle with purpose-designed, in-house wet-lab assays, to discover and design novel RNA therapeutics. In particular, this AI-driven RNA technology can (1) discover novel structural targets across transcripts of interest, thereby enabling the drugging of the transcriptome, and (2) generate and optimize RNA medicines and tools, allowing for their design to desired specifications. Backed by an interdisciplinary team of machine learning researchers and experimental biologists, strategic scientific advisers and world-class investors, Atomic AI is leading the way in AI-augmented structural biology and transforming the design of RNA-targeted and RNA-based medicines to treat undruggable diseases.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2021
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
RNA-targeting small molecules for neurodegenerative and infectious diseases
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
